Abstract
An increased burden of premature atrial contractions (PACs) has long been considered a benign phenomenon. However, strong evidence of their involvement in the occurrence of atrial fibrillation (AF), ischemic stroke, and excess mortality suggests the need for management. The central question to be resolved is whether increased ectopic atrial rhythm is only a predictor of AF or whether it is a marker of atrial cardiomyopathy and therefore of ischemic stroke. After reviewing the pathophysiology of PACs and its impact on patient prognosis, this mini-review proposes to 1) detail the physiological and clinical elements linking PACs and AF, 2) present the evidence in favor of supraventricular ectopic activity as a marker of cardiomyopathy, and 3) outline the current limitations of this concept and the potential future clinical implications.
Introduction
Both premature atrial contractions (PACs) and nonsustained atrial firing are frequent conditions. Historically considered a benign phenomenon, challenging data have highlighted its impact on morbidity and mortality, whether in terms of atrial fibrillation (AF), ischemic stroke or all-cause and cardiovascular mortality (Himmelreich et al., 2019; Huang et al., 2020; Meng et al., 2020). However, the diagnostic and therapeutic management of ectopic atrial rhythm is not yet precisely standardized (Farinha et al., 2022). To improve its management, the central unresolved question is whether an increased PAC burden is only a predictor of AF or whether it is also a marker of atrial cardiomyopathy and subsequent ischemic stroke.
After reviewing the clinical features of PACs, the objective of this mini-review is to provide physiological and clinical data regarding the relationship between nonsustained atrial arrhythmia and AF on one hand and atrial cardiomyopathy on the other hand.
Physiopathology and epidemiology of nonsustained atrial arrhythmia
The complex pathophysiology of PACs and their clinical implications for increased morbidity and mortality are summarized in Figure 1.
FIGURE 1
Physiopathological of nonsustained atrial arrhythmias
PACs are secondary to triggered activities, either by early afterdepolarization in the case of prolongation of the action potential of atrial cardiomyocytes or by delayed afterdepolarization in the case of increased heart rate (Heijman et al., 2014). Calcium-handling abnormalities leading to intracellular calcium overload play a key role in the occurrence of triggered activity secondary to RyR2 dysfunction and increased calcium release from the sarcoplasmic reticulum, and uptake decreases secondary to the SERCA2a channel (Heijman et al., 2012). Atrial structural remodeling, including fibrosis, is mainly involved in conduction velocity abnormalities and re-entrant mechanisms leading to the initiation and maintenance of sustained arrhythmia. However, atrial structural remodeling is also involved in the occurrence of triggered activities by two distinct mechanisms. Abnormalities in calcium handling are increased in cases of significant structural remodeling (Burstein and Nattel, 2008; Choi et al., 2012), and afterdepolarizations can be initiated by direct cardiomyocyte-fibroblast interactions (Yue et al., 2011). Thus, nonsustained atrial arrhythmias are mainly promoted by electrical atrial remodeling but could also be driven by structural remodeling (Schotten et al., 2011).
Autonomic nervous system (ANS) abnormalities play a crucial role in the occurrence of supraventricular ectopic activity (Chen et al., 2014). At the biochemical level, sympathetic stimulation via β receptors is a trigger for calcium release from the sarcoplasmic reticulum (Shen et al., 2012). This could explain the increase in PAC burden during physical activity (Younis et al., 2018). Both the sympathetic and parasympathetic systems are involved in the occurrence of PACs by increasing the calcium transient and heterogeneously reducing action potentials. Atrial cavities are highly innervated by the ANS via the ganglionated plexi and the left atrial ridge, mainly at the level of Marshall’s vein (Lin et al., 2008). Ablation of the ANS connections leads to a drastic reduction in the PAC burden in an animal model (Lu et al., 2009). Global ANS breakdown is also implicated. PAC burden in a population with chronic autonomic failure is associated with decreased sympathetic and parasympathetic activity (Goldstein, 2010). In a large cohort study, PAC burden was associated with both ANS imbalance and decreased global activity (Huang et al., 2020). ANS abnormalities seem to be involved in PAC physiopathology through structural remodeling. Independent of blood pressure changes, renal denervation leads to a decrease in PAC burden (Schirmer et al., 2015) and LA dilation (McLellan et al., 2015).
Acute inflammation is a major risk factor for PAC, such as that occurring in the postoperative period (Jidéus et al., 2006; Dobrev et al., 2019). Chronic inflammation involving the enhancement of oxidative stress also seems to be involved in PAC physiopathology (Anumonwo et al., 2017; Shen et al., 2019).
Epidemiology of nonsustained atrial arrhythmia
Different risk factors are associated with PAC occurrence (Kerola et al., 2019), such as aging (Tasaki et al., 2006; Conen et al., 2012), coronary artery disease (Zoni Berisso et al., 1986), obstructive sleep apnea (Rossi et al., 2013; Kawano et al., 2014), history of cardiovascular disease, heart failure, structural heart disease, physical activity, dyslipidemia, drugs (Conen et al., 2012), and chronic obstructive pulmonary disease (Kusunoki et al., 2016).
Epidemiologically, PACs are common in the general female (Sobotka et al., 1981) and male (Brodsky et al., 1977) populations. Only 1% of individuals in the general population do not present any PACs over a 24-h recording (Conen et al., 2012), and the PAC prevalence based on a 12-lead ECG is approximately 0.5% (Loomba et al., 2018).
Three recent meta-analyses assessed the association between PACs, morbidity, and mortality (Himmelreich et al., 2019; Huang et al., 2020; Meng et al., 2020). The presence of a significant PAC burden is associated with a 3-fold increase in AF occurrence and is independently associated with a 2-fold increase. Nonsustained atrial arrhythmia is also associated with all-cause mortality in both univariate (OR = 2.15) and multivariate (OR = 1.5) analyses. These results are conflicting since another study identified only PVC-associated PACs as a predictor of all-cause mortality (Cheriyath et al., 2011). Increased PAC burden is a predictor of ischemic stroke occurrence (OR between 2.20 and 2.54) and seems to be independently associated (adjusted OR between 1.41 and 2.23). This association was studied not only in the general population (Kamel et al., 2013) but also among patients exhibiting an ischemic stroke with an unknown origin after a systematic evaluation, i.e., an embolic stroke from an undetermined source (ESUS) (Qureshi et al., 2014). The association between increased PAC burden and potential morbidities is stronger in women (O’Neal et al., 2016a).
Nonsustained atrial arrhythmias are therefore associated with AF occurrence. However, there are two hypotheses to explain this association: either PACs are an epidemiological risk marker for AF, or there is a causal relationship between these two conditions.
Nonsustained atrial arrhythmia as a predictor of atrial fibrillation
Physiopathological relationship between premature atrial contractions and atrial fibrillation
The majority of supraventricular tachyarrhythmias, including AF, are triggered by single or consecutive PACs (Durrer et al., 1967), setting a functional line of conduction block (Waldo, 2002). The PAC site plays an important role in the initiation of AF. The pulmonary veins (PVs), as the preferential site of AF occurrence secondary to nonsustained atrial arrhythmias, were reported for the first time in 1998 (Haïssaguerre et al., 1998). Although one-half of the PACs registered in AF patients are located in extra-PV sites, both PACs from PVs and PACs with a bifocal origin are more susceptible to inducing AF (Schmitt et al., 2002). PV-related PACs are also involved in the initiation of atrial flutter (Schneider et al., 2015). A topographic mismatch between arrhythmogenic sites, such as PVs and the superior vena cava, and non-AF locations is steady-grounded (Wang et al., 2017).
Although the majority of AF episodes are preceded by an increase in atrial ectopic rhythm (Dimmer et al., 2003), only 40% of PACs are responsible for sustained arrhythmia in the AF population (Schmitt et al., 2002), and the PAC burden has a poor predictive capacity for AF initiation (Hnatkova et al., 1997). Several electrophysiological features are needed to initiate PAC-related AF. Although few cases of late-coupling PAC-induced AF have been reported (Kinoshita and Katoh, 2007), PAC-inducing AF has a short coupling interval (Capucci et al., 1992). Patients with PAC-induced AF face prolonged refractory periods after PAC, while PAC tends to shorten the dispersion of atrial refractory periods when patients are free of sustained arrhythmia (Chauvin and Brechenmacher, 1989). Finally, PACs may induce calcium-handling abnormalities and spatial and dynamic dispersion of repolarization duration among atrial cardiomyocytes, including discordant alternans, causing conduction block, re-entry, and AF initiation (Gong et al., 2007). The sites with the largest vulnerable window are located in the PVs, highlighting the link between electrophysiological features and preferential PAC sites.
Some modulators, such as ANS imbalance, play a crucial role in AF promotion (Scherlag et al., 2005). The occurrence of PACs in patients presenting variability in the PR interval leads to a higher AF risk (Chun et al., 2016). Enhancement of vagal tone seems to be a trigger of PAC-induced AF initiation: heart rate turbulence, a marker of vagal tone, is higher in pre-AF periods and is also associated with PAC burden (Vikman et al., 2005).
Clinical evidence of premature atrial contraction-induced atrial fibrillation mechanism
The first invasive AF ablation was based on radiofrequency ablation of PVs located in the PVs and was proven to be an effective therapeutic strategy allowing a 62% rate of AF-free survival after a 1-year follow-up (Haïssaguerre et al., 1998). An increased PAC burden after AF ablation is associated with the failure of PV isolation assessed in a redo procedure. A redo PV isolation procedure leads to a drastic decrease in PAC and AF burden, suggesting the crucial role of PACs located in the PVs as triggers of AF (Yamane et al., 2006). Patients with AF recurrence after PV isolation had a lower PAC burden before ablation, suggesting the significant role of PACs from PVs in the proarrhythmic process (Hamon et al., 2021).
On the other hand, extra-PV PACs are a marker of atrial remodeling. Both PAC burden (Gang et al., 2015) and rapid atrial firing (Inoue et al., 2020) after successful PV isolation are predictors of AF recurrence during long-term follow-up. Thus, it seems that ectopic atrial rhythm is a marker of atrial substrate responsible for AF recurrence after PV isolation, although a failure of PV isolation cannot be ruled out.
PAC burden seems to be associated with long-term recurrence of AF after AF ablation (Egami et al., 2021) regardless of AF recurrence during the blanking period. Interestingly, a patient with a low PAC burden and early blanking period-related AF recurrence has a low risk of long-term AF recurrence (Alhede et al., 2018).
Consistent data suggest a physiopathological and clinical relationship between PACs and sustained supraventricular arrhythmia, leading to electrophysiological atrial remodeling. However, the concept of increased PAC burden as a marker of global atrial remodeling, so-called atrial cardiomyopathy, challenges the classic paradigm.
Premature atrial contractions as a marker of atrial cardiomyopathy
The concept of atrial cardiomyopathy
Atrial cardiomyopathy was precisely defined in 2017 by an expert consensus as any complex structural, architectural, contractile, or electrophysiological changes affecting the atria with the potential to produce clinically relevant manifestations (Goette et al., 2017). This new paradigm suggests that both AF and cardioembolic events are secondary to atrial cardiomyopathy and challenges the traditional concept of AF as directly inducing thromboembolic events (Guichard and Nattel, 2017). Emerging data suggest the lack of a direct link between AF and stroke. First, although the epidemiological relationship between AF and ischemic stroke is steady-grounded, there is a lack of clear temporal association between AF and stroke occurrence as assessed in the ASSERT (Healey et al., 2012) and TRENDS (Daoud et al., 2011) trials. Second, the thromboembolic risk (TER) is not homogeneous in the AF population and is highly influenced by the presence of cardiovascular risk factors (Lip et al., 2010). The CHA2DS2-VASc score is a clinical diagnostic tool allowing for TER assessment (Hindricks et al., 2020) and encompasses different risk factors for atrial cardiomyopathy, such as heart failure, hypertension, diabetes mellitus, vascular disease, and aging (Guichard and Nattel, 2017). Third, the benefit of anticoagulation secondary to subclinical AF screening on the TER is uncertain (Svendsen et al., 2021; Svennberg et al., 2021). Finally, early rhythm control in AF patients decreases ischemic stroke occurrence (Kirchhof et al., 2020), but the underlying mechanism is not understood. This finding could be explained by a decrease in AF burden or the prevention of AF-induced atrial cardiomyopathy.
A cardioembolic stroke could occur in the presence of atrial cardiomyopathy even before AF occurrence, as encountered in cases of cardiac amyloidosis (Dubrey et al., 1995). A diseased left atrium is characterized by inflammation (Kamel et al., 2016), endothelial dysfunction (Cai et al., 2002), fibrosis (Burstein and Nattel, 2008), contractile dysfunction (Mihm et al., 2001), and dilation (Vaziri et al., 1994). However, there is currently a lack of standardized and validated clinical assessment of atrial cardiomyopathy and a need for validation of clinical markers of atrial cardiomyopathy (Bisbal et al., 2020). Assessment of the PAC burden could be a relevant parameter to clinically characterize atrial cardiomyopathy (Farinha et al., 2022).
Nonsustained atrial arrhythmias as a marker of thromboembolic risk
Supraventricular ectopic activity is an independent predictor of stroke occurrence (Huang et al., 2020) after adjustment for cardiovascular risk factors (Engström et al., 2000), ECG abnormalities (Murakoshi et al., 2015), ethnicity, and cardiovascular medication (O’Neal et al., 2016a). Furthermore, an increased PAC burden is associated with nonlacunar ischemia but not with all-cause stroke, suggesting a link between PACs and cardioembolic events (O’Neal et al., 2016a). Atrial firing is also an independent predictor of ischemic stroke recurrence in an ESUS population (Sejr et al., 2020).
Different mechanisms could underlie the relationship between ectopic atrial rhythm and ischemic stroke. PACs and ischemic stroke share the same risk factors, such as aging, heart failure (Conen et al., 2012), and OSA (Kawano et al., 2014). However, the PAC burden is still predictive of stroke occurrence even after a seemingly thorough adjustment for shared risk factors (Huang et al., 2020). PAC as a pre-AF status could highlight in an upstream manner the role of AF regarding cardioembolic risk. AF is often asymptomatic (Hindricks et al., 2020), and long-term diagnostic tools such as the smartwatch (Perez et al., 2019) and internal loop recorder (Gladstone et al., 2015) are useful to diagnose subclinical AF. PACs as an AF predictor could be a marker of undiagnosed AF leading to ischemic stroke. However, an increased PAC burden is a predictor of ischemic stroke occurrence, independent of AF occurrence (Larsen et al., 2015). PACs can directly lead to abnormalities in atrial function. Patients with a high PAC burden seem to have reduced atrial function (O’Neal et al., 2016b), leading to a decrease in left atrial stroke volume and potential thrombus formation (Goyal and Spodick, 2001). Nonsustained atrial arrhythmia seems to be a clinical marker of atrial cardiomyopathy leading to an increased cardioembolic risk. The risk of ischemic stroke recurrence in ESUS patients with a CHA2DS2-VASc score > 2 is associated with increased PAC burden or AF (Larsen et al., 2015). PAC occurrence is associated with LA dilation and risk factors for atrial cardiomyopathy in an ESUS population (Pinho et al., 2015; Vinther et al., 2017; Cha et al., 2020), suggesting that PACs are a clinical marker of atrial cardiomyopathy (Sajeev et al., 2019). Furthermore, the presence of PACs after AF ablation results in a significant decrease in left atrial reverse remodeling (Hasegawa et al., 2019), highlighting a direct role of PACs in atrial cardiomyopathy.
Current limitations and clinical implications
The relationship between nonsustained atrial tachyarrhythmias and atrial cardiomyopathy is supported by different epidemiological and clinical features. However, several issues remain unresolved regarding the detection of atrial cardiomyopathy and the contribution of the assessment of ectopic atrial rhythm on the one hand and the therapeutic management of atrial cardiomyopathy on the other hand (Figure 2).
FIGURE 2
The threshold of PAC burden predicting atrial cardiomyopathy has to be precised. Indeed, the cutoffs used in the different studies reported in this review are heterogeneous, e.g., at least one PAC per 24 h (O’Neal et al., 2016a), more than 72 PACs in 24 h (Lin et al., 2015), and more than 30 PACs per hour (Larsen et al., 2015), although the threshold of 500 PACs/24 h has been proposed in a consensus paper (Arnar et al., 2019). A standardized methodology for the evaluation of atrial hyperexcitability has not yet been validated. Different diagnostic tools are used in clinical practice, such as standard 12-lead ECG (Inohara et al., 2013; Qureshi et al., 2014; O’Neal et al., 2016a), 15-s (Murakoshi et al., 2015) to 2-min (Cheriyath et al., 2011) ECG, and 24-h (Engström et al., 2000; Acharya et al., 2015) to 48-h (Binici et al., 2010; Larsen et al., 2015) Holter monitoring. Screening for nonsustained atrial arrhythmia will need to be considered in light of the use of new diagnostic tools such as implantable loop recorders (Kochhäuser et al., 2014; Gladstone et al., 2015) and digital devices (Varma et al., 2021).
Standardized therapeutic management of nonsustained atrial arrhythmia is not currently consensual. Regarding a rhythm control strategy using beta-blockers, prospective interventional trials are lacking, and observational studies suggest a lack of benefit in terms of AF occurrence and ischemic stroke (Huang et al., 2022). Invasive PAC ablation is an effective strategy regarding the PAC burden (Wang et al., 2017), but its value in improving clinical prognosis has not been depicted. Regarding cardioembolic risk prevention, no randomized controlled trials (RCTs) have evaluated the benefit of anticoagulation in cases of a high PAC burden. It is not clear whether PACs directly lead to TER or are a marker of atrial cardiomyopathy. If the latter is true, therapeutic management of PACs would be unnecessary to reduce the occurrence of ischemic stroke (Marcus and Dewland, 2015; Alhede et al., 2017; Heijman et al., 2017).
Assessment of a high PAC burden could be a relevant diagnostic tool for the characterization of atrial cardiomyopathy but does not lead to the detection of structural and functional atrial abnormalities on its own: a combined diagnostic approach seems necessary. Other noninvasive electrophysiological tools, such as the P-wave terminal force in lead V1, the P-wave duration, the maximum P-wave area, and advanced interatrial block, could be used (MÄ…czyÅ„ska et al., 2018) since they are strong predictors of AF occurrence and ischemic stroke occurrence in patients with ESUS and the general population (Kamel et al., 2015b, 2015a; He et al., 2017; MartÃnez-Sellés et al., 2020). Different biomarkers of atrial endothelial dysfunction, inflammation, coagulation, or myocardial stress also appear to be relevant diagnostic tools (Markus et al., 2021). Imaging could also play an essential role in assessing atrial morphological abnormalities using echocardiography (Xu et al., 2020) and assessments of structural abnormalities and fibrosis (Akoum et al., 2013).
The setting up of therapeutic strategies targeting atrial cardiomyopathy remains poorly studied. In AF patients, the current guidelines highlight the potential role of upstream therapies such as angiotensin-converting enzyme inhibitors, beta-blockers, and statins to prevent atrial remodeling as a rhythm control strategy (Hindricks et al., 2020). However, conflicting results among various studies limit the recommendation of upstream therapies for the general AF population. Cardioembolic risk prevention using anticoagulation in a population exhibiting atrial cardiomyopathy without AF has not been evaluated thus far (Bayés de Luna et al., 2017). The ongoing ARCADIA study is the first RCT evaluating the benefit of anticoagulation with respect to the occurrence of all-cause stroke in patients with a history of ESUS and atrial cardiomyopathy (Kamel et al., 2019). Atrial cardiomyopathy is not defined by a high PAC burden but using composite criteria, including increased P-wave terminal force in V1, NT-proBNP > 250 pg/ml, and left atrial dilation on an echocardiogram.
Conclusion
Nonsustained atrial arrhythmia does not appear to be solely a predictor of AF but is also an independent predictor of ischemic stroke via the presence of atrial cardiomyopathy. However, the diagnostic and therapeutic management of a high PAC burden to prevent AF and ischemic stroke remains partially studied.
Statements
Author contributions
J-BG and EG performed the literature search and wrote the manuscript. All authors reviewed the manuscript and approved the final version for submission. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.
Funding
This work was supported in part by a Grant No. PI19/00573 of Instituto de Salud Carlos III, Madrid, Spain.
Acknowledgments
J-BG thanks the French Federation of Cardiology (FFC) for institutional grant support.
Conflict of interest
J-BG reports honoraries as a consultant, and lecturer from Abbott Medical and Microport CRM, and received an unrestricted grant from Abbott Medical. LM reports honoraries as a consultant, lecturer, and Advisory Board from Boston Scientific, Abbott Medical, Johnson & Johnson, and Medtronic; He is a shareholder of Galgo Medical SL.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AcharyaT.TringaliS.BhullarM.NalbandyanM.IlineniV. K.CarbajalE.et al (2015). Frequent atrial premature complexes and their association with risk of atrial fibrillation. Am. J. Cardiol.116, 1852–1857. 10.1016/j.amjcard.2015.09.025
2
AkoumN.FernandezG.WilsonB.McgannC.KholmovskiE.MarroucheN. (2013). Association of atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast on transesophageal echocardiography in patients with atrial fibrillation. J. Cardiovasc. Electrophysiol.24, 1104–1109. 10.1111/jce.12199
3
AlhedeC.JohannessenA.DixenU.JensenJ. S.RaatikainenP.HindricksG.et al (2018). Higher burden of supraventricular ectopic complexes early after catheter ablation for atrial fibrillation is associated with increased risk of recurrent atrial fibrillation. Europace20, 50–57. 10.1093/europace/euw329
4
AlhedeC.LauridsenT. K.JohannessenA.DixenU.JensenJ. S.RaatikainenP.et al (2017). Antiarrhythmic medication is superior to catheter ablation in suppressing supraventricular ectopic complexes in patients with atrial fibrillation. Int. J. Cardiol.244, 186–191. 10.1016/j.ijcard.2017.05.028
5
AnumonwoJ. M.JalifeJ.GoldsteinD. R. (2017). Triple threat: Adiposity, aging, atrial fibrillation. Aging (Albany NY)9, 2235–2236. 10.18632/aging.101318
6
ArnarD. O.MairesseG. H.BorianiG.CalkinsH.ChinA.CoatsA.et al (2019). Management of asymptomatic arrhythmias: A European heart rhythm association (EHRA) consensus document, endorsed by the heart failure association (HFA), heart rhythm society (HRS), asia pacific heart rhythm society (APHRS), cardiac arrhythmia society of southern africa (CASSA), and Latin America heart rhythm society (LAHRS). Europace.21, 844–845. 10.1093/europace/euz046
7
Bayés de LunaA.BaranchukA.MartÃnez-SellésM.PlatonovP. G. (2017). Anticoagulation in patients at high risk of stroke without documented atrial fibrillation. Time for a paradigm shift?Ann. Noninvasive Electrocardiol.22, e12417. 10.1111/anec.12417
8
BiniciZ.IntzilakisT.NielsenO. W.KøberL.SajadiehA. (2010). Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation121, 1904–1911. 10.1161/CIRCULATIONAHA.109.874982
9
BisbalF.BaranchukA.BraunwaldE.LunaA. B. deBayés-GenÃsA. (2020). Atrial failure as a clinical entity: JACC review topic of the week. J. Am. Coll. Cardiol.75, 222–232. 10.1016/j.jacc.2019.11.013
10
BrodskyM.WuD.DenesP.KanakisC.RosenK. M. (1977). Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am. J. Cardiol.39, 390–395. 10.1016/S0002-9149(77)80094-5
11
BursteinB.NattelS. (2008). Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol.51, 802–809. 10.1016/j.jacc.2007.09.064
12
CaiH.LiZ.GoetteA.MeraF.HoneycuttC.FeterikK.et al (2002). Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: Potential mechanisms for atrial thrombosis and stroke. Circulation106, 2854–2858. 10.1161/01.cir.0000039327.11661.16
13
CapucciA.SantarelliA.BorianiG.MagnaniB. (1992). Atrial premature beats coupling interval determines lone paroxysmal atrial fibrillation onset. Int. J. Cardiol.36, 87–93. 10.1016/0167-5273(92)90112-g
14
ChaJ.-J.ChungH.UhmJ.-S.JoungB.PakH.-N.LeeM.-H.et al (2020). Multiple atrial premature contractions predict stroke recurrence in patients with cryptogenic stroke and concomitant non-sustained atrial tachycardia. Int. J. Arrhythmia21, 5. 10.1186/s42444-020-00014-8
15
ChauvinM.BrechenmacherC. (1989). Atrial refractory periods after atrial premature beats in patients with paroxysmal atrial fibrillation. Pacing Clin. Electrophysiol.12, 1018–1026. 10.1111/j.1540-8159.1989.tb01919.x
16
ChenP.-S.ChenL. S.FishbeinM. C.LinS.-F.NattelS. (2014). Role of the autonomic nervous system in atrial fibrillation: Pathophysiology and therapy. Circ. Res.114, 1500–1515. 10.1161/CIRCRESAHA.114.303772
17
CheriyathP.HeF.PetersI.LiX.AlagonaP.WuC.et al (2011). Relation of atrial and/or ventricular premature complexes on a two-minute rhythm strip to the risk of sudden cardiac death (the Atherosclerosis Risk in Communities [ARIC] study). Am. J. Cardiol.107, 151–155. 10.1016/j.amjcard.2010.09.002
18
ChoiE.-K.ChangP.-C.LeeY.-S.LinS.-F.ZhuW.MaruyamaM.et al (2012). Triggered firing and atrial fibrillation in transgenic mice with selective atrial fibrosis induced by overexpression of TGF-β1. Circ. J.76, 1354–1362. 10.1253/circj.cj-11-1301
19
ChunK. J.HwangJ. K.ParkS.-J.OnY. K.KimJ. S.ParkK.-M. (2016). Electrical PR interval variation predicts new occurrence of atrial fibrillation in patients with frequent premature atrial contractions. Med. Baltim.95, e3249. 10.1097/MD.0000000000003249
20
ConenD.AdamM.RocheF.BarthelemyJ.-C.Felber DietrichD.ImbodenM.et al (2012). Premature atrial contractions in the general population: Frequency and risk factors. Circulation126, 2302–2308. 10.1161/CIRCULATIONAHA.112.112300
21
DaoudE. G.GlotzerT. V.WyseD. G.EzekowitzM. D.HilkerC.KoehlerJ.et al (2011). Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: A subgroup analysis of TRENDS. Heart rhythm.8, 1416–1423. 10.1016/j.hrthm.2011.04.022
22
DimmerC.Szili-TorokT.TavernierR.VerstratenT.JordaensL. J. (2003). Initiating mechanisms of paroxysmal atrial fibrillation. Europace5, 1–9. 10.1053/eupc.2002.0273
23
DobrevD.AguilarM.HeijmanJ.GuichardJ.NattelS. (2019). Postoperative atrial fibrillation: Mechanisms, manifestations and management. Nat. Rev. Cardiol.16, 417–436. 10.1038/s41569-019-0166-5
24
DubreyS.PollakA.SkinnerM.FalkR. H. (1995). Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: Evidence for atrial electromechanical dissociation. Br. Heart J.74, 541–544. 10.1136/hrt.74.5.541
25
DurrerD.SchooL.SchuilenburgR. M.WellensH. J. (1967). The role of premature beats in the initiation and the termination of supraventricular tachycardia in the Wolff-Parkinson-White syndrome. Circulation36, 644–662. 10.1161/01.cir.36.5.644
26
EgamiY.UkitaK.KawamuraA.NakamuraH.MatsuhiroY.YasumotoK.et al (2021). Novel score to predict very late recurrences after catheter ablation of atrial fibrillation. Am. J. Cardiol.141, 49–55. 10.1016/j.amjcard.2020.11.008
27
EngströmG.HedbladB.Juul-MöllerS.TydénP.JanzonL. (2000). Cardiac arrhythmias and stroke: Increased risk in men with high frequency of atrial ectopic beats. Stroke31, 2925–2929. 10.1161/01.str.31.12.2925
28
FarinhaJ. M.GuptaD.LipG. Y. H. (2022). Frequent premature atrial contractions as a signalling marker of atrial cardiomyopathy, incident atrial fibrillation and stroke. Cardiovasc. Res.2022, cvac054. cvac054. 10.1093/cvr/cvac054
29
GangU. J. O.NalliahC. J.LimT. W.ThiagalingamA.KovoorP.RossD. L.et al (2015). Atrial ectopy predicts late recurrence of atrial fibrillation after pulmonary vein isolation. Circ. Arrhythm. Electrophysiol.8, 569–574. 10.1161/CIRCEP.114.002052
30
GladstoneD. J.DorianP.SpringM.PanzovV.MamdaniM.HealeyJ. S.et al (2015). Atrial premature beats predict atrial fibrillation in cryptogenic stroke: Results from the EMBRACE trial. Stroke46, 936–941. 10.1161/STROKEAHA.115.008714
31
GoetteA.KalmanJ. M.AguinagaL.AkarJ.CabreraJ. A.ChenS. A.et al (2017). EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. Heart rhythm.14, e3–e40. 10.1016/j.hrthm.2016.05.028
32
GoldsteinD. S. (2010). Cardiac ectopy in chronic autonomic failure. Clin. Auton. Res.20, 85–92. 10.1007/s10286-009-0043-0
33
GongY.XieF.SteinK. M.GarfinkelA.CulianuC. A.LermanB. B.et al (2007). Mechanism underlying initiation of paroxysmal atrial flutter/atrial fibrillation by ectopic foci: A simulation study. Circulation115, 2094–2102. 10.1161/CIRCULATIONAHA.106.656504
34
GoyalS. B.SpodickD. H. (2001). Electromechanical dysfunction of the left atrium associated with interatrial block. Am. Heart J.142, 823–827. 10.1067/mhj.2001.118110
35
GuichardJ.-B.NattelS. (2017). Atrial cardiomyopathy: A useful notion in cardiac disease management or a passing fad?J. Am. Coll. Cardiol.70, 756–765. 10.1016/j.jacc.2017.06.033
36
HaïssaguerreM.JaïsP.ShahD. C.TakahashiA.HociniM.QuiniouG.et al (1998). Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med.339, 659–666. 10.1056/NEJM199809033391003
37
HamonD.CourtyB.LeenhardtA.LimP.ElbazN.RouffiacS.et al (2021). Predictive value of premature atrial complex characteristics in pulmonary vein isolation for patients with paroxysmal atrial fibrillation. Arch. Cardiovasc. Dis.114, 122–131. 10.1016/j.acvd.2020.09.001
38
HasegawaT.NakanishiK.YoshidaY.UetsuharaT.KosakaM.ShiraiN.et al (2019). Atrial ectopy after pulmonary vein isolation and left heart reverse remodeling in patients with atrial fibrillation. Pacing Clin. Electrophysiol.42, 1125–1132. 10.1111/pace.13747
39
HeJ.TseG.KorantzopoulosP.LetsasK. P.Ali-Hasan-Al-SaeghS.KamelH.et al (2017). P-wave indices and risk of ischemic stroke: A systematic review and meta-analysis. Stroke48, 2066–2072. 10.1161/STROKEAHA.117.017293
40
HealeyJ. S.ConnollyS. J.GoldM. R.IsraelC. W.Van GelderI. C.CapucciA.et al (2012). Subclinical atrial fibrillation and the risk of stroke. N. Engl. J. Med.366, 120–129. 10.1056/NEJMoa1105575
41
HeijmanJ.DobrevD.CrijnsH. J. G. M. (2017). Targeting supraventricular ectopic complexes: Which approach should be used and how does it affect atrial fibrillation?Int. J. Cardiol.244, 202–203. 10.1016/j.ijcard.2017.06.013
42
HeijmanJ.VoigtN.NattelS.DobrevD. (2012). Calcium handling and atrial fibrillation. Wien. Med. Wochenschr.162, 287–291. 10.1007/s10354-012-0109-9
43
HeijmanJ.VoigtN.NattelS.DobrevD. (2014). Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ. Res.114, 1483–1499. 10.1161/CIRCRESAHA.114.302226
44
HimmelreichJ. C. L.LucassenW. A. M.HeugenM.BossuytP. M. M.TanH. L.HarskampR. E.et al (2019). Frequent premature atrial contractions are associated with atrial fibrillation, brain ischaemia, and mortality: A systematic review and meta-analysis. Europace21, 698–707. 10.1093/europace/euy276
45
HindricksG.PotparaT.DagresN.ArbeloE.BaxJ. J.Blomström-LundqvistC.et al (2020). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J.42, 373–498. 10.1093/eurheartj/ehaa612
46
HnatkovaK.MurgatroydF. D.GuoX.CammA. J.MalikM. (1997). Atrial premature beats preceding episodes of paroxysmal atrial fibrillation: Factorial analysis of a prediction system. Pacing Clin. Electrophysiol.20, 2003–2007. 10.1111/j.1540-8159.1997.tb03608.x
47
HuangS.-H.HuY.-F.ChenP.-F.LinY.-J.ChangS.-L.LoL.-W.et al (2020). The presence of ectopic atrial rhythm predicts adverse cardiovascular outcomes in a large hospital-based population. Heart rhythm.17, 967–974. 10.1016/j.hrthm.2020.01.024
48
HuangT.-C.LeeP.-T.HuangM.-S.ChiuP.-H.SuP.-F.LiuP.-Y. (2022). The beneficial effects of beta blockers on the long-term prognosis of patients with premature atrial complexes. Front. Cardiovasc. Med.9, 806743. 10.3389/fcvm.2022.806743
49
InoharaT.KohsakaS.OkamuraT.WatanabeM.NakamuraY.HigashiyamaA.et al (2013). Long-term outcome of healthy participants with atrial premature complex: A 15-year follow-up of the NIPPON DATA 90 cohort. PLoS One8, e80853. 10.1371/journal.pone.0080853
50
InoueH.TanakaN.TanakaK.NinomiyaY.HiraoY.OkaT.et al (2020). Burden and long firing of premature atrial contraction early after catheter ablation predict late recurrence of atrial fibrillation. Circ. J.84, 894–901. 10.1253/circj.CJ-19-0976
51
JidéusL.KesekM.JoachimssonP.-O.EricsonM.NilssonL.Blomström-LundqvistC. (2006). The role of premature atrial contractions as the main triggers of postoperative atrial fibrillation. J. Electrocardiol.39, 48–54. 10.1016/j.jelectrocard.2005.07.010
52
KamelH.ElkindM. S. V.BhaveP. D.NaviB. B.OkinP. M.IadecolaC.et al (2013). Paroxysmal supraventricular tachycardia and the risk of ischemic stroke. Stroke44, 1550–1554. 10.1161/STROKEAHA.113.001118
53
KamelH.HunterM.MoonY. P.YaghiS.CheungK.Di TullioM. R.et al (2015a). Electrocardiographic left atrial abnormality and risk of stroke: Northern manhattan study. Stroke46, 3208–3212. 10.1161/STROKEAHA.115.009989
54
KamelH.LongstrethW.TirschwellD. L.KronmalR. A.BroderickJ. P.PaleschY. Y.et al (2019). The AtRial Cardiopathy and Antithrombotic Drugs in prevention after cryptogenic stroke randomized trial: Rationale and methods. Int. J. Stroke14, 207–214. 10.1177/1747493018799981
55
KamelH.OkinP. M.ElkindM. S. V.IadecolaC. (2016). Atrial fibrillation and mechanisms of stroke: Time for a new model. Stroke47, 895–900. 10.1161/STROKEAHA.115.012004
56
KamelH.O’NealW. T.OkinP. M.LoehrL. R.AlonsoA.SolimanE. Z. (2015b). Electrocardiographic left atrial abnormality and stroke subtype in the atherosclerosis risk in communities study. Ann. Neurol.78, 670–678. 10.1002/ana.24482
57
KawanoY.TamuraA.OnoK.KadotaJ. (2014). Association between obstructive sleep apnea and premature supraventricular contractions. J. Cardiol.63, 69–72. 10.1016/j.jjcc.2013.07.003
58
KerolaT.DewlandT. A.VittinghoffE.HeckbertS. R.SteinP. K.MarcusG. M. (2019). Predictors of atrial ectopy and their relationship to atrial fibrillation risk. Europace21, 864–870. 10.1093/europace/euz008
59
KinoshitaS.KatohT. (2007). Paroxysmal atrial fibrillation initiated by late coupled atrial extrasystoles. J. Cardiovasc. Med.8, 940–942. 10.2459/JCM.0b013e3280127b2b
60
KirchhofP.CammA. J.GoetteA.BrandesA.EckardtL.ElvanA.et al (2020). Early rhythm-control therapy in patients with atrial fibrillation. N. Engl. J. Med.383, 1305–1316. 10.1056/NEJMoa2019422
61
KochhäuserS.DecheringD. G.DittrichR.ReinkeF.RitterM. A.RamtinS.et al (2014). Supraventricular premature beats and short atrial runs predict atrial fibrillation in continuously monitored patients with cryptogenic stroke. Stroke45, 884–886. 10.1161/STROKEAHA.113.003788
62
KusunokiY.NakamuraT.HattoriK.MotegiT.IshiiT.GemmaA.et al (2016). Atrial and ventricular arrhythmia-associated factors in stable patients with chronic obstructive pulmonary disease. Respiration.91, 34–42. 10.1159/000442447
63
LarsenB. S.KumarathuraiP.FalkenbergJ.NielsenO. W.SajadiehA. (2015). Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation. J. Am. Coll. Cardiol.66, 232–241. 10.1016/j.jacc.2015.05.018
64
LinC.-Y.LinY.-J.ChenY.-Y.ChangS.-L.LoL.-W.ChaoT.-F.et al (2015). Prognostic significance of premature atrial complexes burden in prediction of long-term outcome. J. Am. Heart Assoc.4, e002192. 10.1161/JAHA.115.002192
65
LinJ.ScherlagB. J.LuZ.ZhangY.LiuS.PattersonE.et al (2008). Inducibility of atrial and ventricular arrhythmias along the ligament of marshall: Role of autonomic factors. J. Cardiovasc. Electrophysiol.19, 955–962. 10.1111/j.1540-8167.2008.01159.x
66
LipG. Y. H.NieuwlaatR.PistersR.LaneD. A.CrijnsH. J. G. M. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest137, 263–272. 10.1378/chest.09-1584
67
LoombaR.AielloS.AggarwalS.AggarwalG.AroraR. (2018). Premature atrial and ventricular contractions: Prevalence, clinical evaluation, and associated morbidity as noted from the nationwide inpatient sample. EC Cardiol.5, 10–16.
68
LuZ.ScherlagB. J.LinJ.YuL.GuoJ.-H.NiuG.et al (2009). Autonomic mechanism for initiation of rapid firing from atria and pulmonary veins: Evidence by ablation of ganglionated plexi. Cardiovasc. Res.84, 245–252. 10.1093/cvr/cvp194
69
MączyńskaJ.Kurkowska-JastrzębskaI.DąbrowskiR. (2018). Mechanisms of cardioembolic stroke revisited. Atrial cardiopathy. Kardiol. Pol.76, 314–319. 10.5603/KP.a2017.0212
70
MarcusG. M.DewlandT. A. (2015). Premature atrial contractions. J. Am. Coll. Cardiol.66, 242–244. 10.1016/j.jacc.2015.04.069
71
MarkusA.ValerieS.MiraK. (2021). Promising biomarker candidates for cardioembolic stroke etiology. A Brief Narrat. Rev. Curr. Opin. Front. Neurology12, 624930. 10.3389/fneur.2021.624930
72
MartÃnez-SellésM.ElosuaR.IbarrolaM.de AndrésM.DÃez-VillanuevaP.Bayés-GenisA.et al (2020). Advanced interatrial block and P-wave duration are associated with atrial fibrillation and stroke in older adults with heart disease: The BAYES registry. Europace22, 1001–1008. 10.1093/europace/euaa114
73
McLellanA. J. A.SchlaichM. P.TaylorA. J.PrabhuS.HeringD.HammondL.et al (2015). Reverse cardiac remodeling after renal denervation: Atrial electrophysiologic and structural changes associated with blood pressure lowering. Heart rhythm.12, 982–990. 10.1016/j.hrthm.2015.01.039
74
MengL.TsiaousisG.HeJ.TseG.AntoniadisA. P.KorantzopoulosP.et al (2020). Excessive supraventricular ectopic activity and adverse cardiovascular outcomes: A systematic review and meta-analysis. Curr. Atheroscler. Rep.22, 14. 10.1007/s11883-020-0832-4
75
MihmM. J.YuF.CarnesC. A.ReiserP. J.McCarthyP. M.Van WagonerD. R.et al (2001). Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation104, 174–180. 10.1161/01.cir.104.2.174
76
MurakoshiN.XuD.SairenchiT.IgarashiM.IrieF.TomizawaT.et al (2015). Prognostic impact of supraventricular premature complexes in community-based health checkups: The ibaraki prefectural health study. Eur. Heart J.36, 170–178. 10.1093/eurheartj/ehu407
77
O’NealW. T.KamelH.KleindorferD.JuddS. E.HowardG.HowardV. J.et al (2016a). Premature atrial contractions on the screening electrocardiogram and risk of ischemic stroke: The reasons for geographic and racial differences in stroke study. Neuroepidemiology47, 53–58. 10.1159/000448619
78
O’NealW. T.ZhangZ.-M.LoehrL. R.ChenL. Y.AlonsoA.SolimanE. Z. (2016b). Electrocardiographic advanced interatrial block and atrial fibrillation risk in the general population. Am. J. Cardiol.117, 1755–1759. 10.1016/j.amjcard.2016.03.013
79
PerezM. V.MahaffeyK. W.HedlinH.RumsfeldJ. S.GarciaA.FerrisT.et al (2019). Large-scale Assessment of a smartwatch to identify atrial fibrillation. N. Engl. J. Med.381, 1909–1917. 10.1056/NEJMoa1901183
80
PinhoJ.BragaC. G.RochaS.SantosA. F.GomesA.CabreiroA.et al (2015). Atrial ectopic activity in cryptogenic ischemic stroke and TIA: A risk factor for recurrence. J. Stroke Cerebrovasc. Dis.24, 507–510. 10.1016/j.jstrokecerebrovasdis.2014.09.029
81
QureshiW.ShahA. J.SalahuddinT.SolimanE. Z. (2014). Long-term mortality risk in individuals with atrial or ventricular premature complexes (results from the Third National Health and Nutrition Examination Survey). Am. J. Cardiol.114, 59–64. 10.1016/j.amjcard.2014.04.005
82
RossiV. A.StradlingJ. R.KohlerM. (2013). Effects of obstructive sleep apnoea on heart rhythm. Eur. Respir. J.41, 1439–1451. 10.1183/09031936.00128412
83
SajeevJ. K.KoshyA. N.DeweyH.KalmanJ. M.RajakariarK.TanM. C.et al (2019). Association between excessive premature atrial complexes and cryptogenic stroke: Results of a case–control study. BMJ Open9, e029164. 10.1136/bmjopen-2019-029164
84
ScherlagB. J.YamanashiW.PatelU.LazzaraR.JackmanW. M. (2005). Autonomically induced conversion of pulmonary vein focal firing into atrial fibrillation. J. Am. Coll. Cardiol.45, 1878–1886. 10.1016/j.jacc.2005.01.057
85
SchirmerS. H.SayedM. M. Y. A.ReilJ.-C.LavallD.UkenaC.LinzD.et al (2015). Atrial remodeling following catheter-based renal denervation occurs in a blood pressure– and heart rate–independent manner. JACC. Cardiovasc. Interv.8, 972–980. 10.1016/j.jcin.2015.02.014
86
SchmittC.NdrepepaG.WeberS.SchmiederS.WeyerbrockS.SchneiderM.et al (2002). Biatrial multisite mapping of atrial premature complexes triggering onset of atrial fibrillation. Am. J. Cardiol.89, 1381–1387. 10.1016/s0002-9149(02)02350-0
87
SchneiderR.LauschkeJ.TischerT.SchneiderC.VossW.MoehlenkampF.et al (2015). Pulmonary vein triggers play an important role in the initiation of atrial flutter: Initial results from the prospective randomized Atrial Fibrillation Ablation in Atrial Flutter (Triple A) trial. Heart rhythm.12, 865–871. 10.1016/j.hrthm.2015.01.040
88
SchottenU.VerheuleS.KirchhofP.GoetteA. (2011). Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol. Rev.91, 265–325. 10.1152/physrev.00031.2009
89
SejrM. H.MayO.DamgaardD.BruunN. H.NielsenJ. C. (2020). Burden of premature atrial complexes and risk of recurrent stroke and death in patients with mild to moderate ischemic stroke. J. Stroke Cerebrovasc. Dis.29, 104490. 10.1016/j.jstrokecerebrovasdis.2019.104490
90
ShenM. J.AroraR.JalifeJ. (2019). Atrial myopathy. JACC. Basic Transl. Sci.4, 640–654. 10.1016/j.jacbts.2019.05.005
91
ShenM. J.ChoiE.-K.TanA. Y.LinS.-F.FishbeinM. C.ChenL. S.et al (2012). Neural mechanisms of atrial arrhythmias. Nat. Rev. Cardiol.9, 30–39. 10.1038/nrcardio.2011.139
92
SobotkaP. A.MayerJ. H.BauernfeindR. A.KanakisC.RosenK. M. (1981). Arrhythmias documented by 24-hour continuous ambulatory electrocardiographic monitoring in young women without apparent heart disease. Am. Heart J.101, 753–759. 10.1016/0002-8703(81)90611-6
93
SvendsenJ. H.DiederichsenS. Z.HøjbergS.KriegerD. W.GraffC.KronborgC.et al (2021). Implantable loop recorder detection of atrial fibrillation to prevent stroke (the LOOP study): A randomised controlled trial. Lancet398, 1507–1516. 10.1016/S0140-6736(21)01698-6
94
SvennbergE.FribergL.FrykmanV.Al-KhaliliF.EngdahlJ.RosenqvistM. (2021). Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): A multicentre, parallel group, unmasked, randomised controlled trial. Lancet398, 1498–1506. 10.1016/S0140-6736(21)01637-8
95
TasakiH.SeritaT.UeyamaC.KitanoK.SetoS.YanoK.et al (2006). Longitudinal age-related changes in 24-hour total heart beats and premature beats and their relationship in healthy elderly subjects. Int. Heart J.47, 549–563. 10.1536/ihj.47.549
96
VarmaN.CygankiewiczI.TurakhiaM.HeidbuchelH.HuY.ChenL. Y.et al (2021). 2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in arrhythmia management: Digital medical tools for heart rhythm professionals. Eur. Heart J. - Digital Health2, 7–48. 10.1093/ehjdh/ztab001
97
VaziriS. M.LarsonM. G.BenjaminE. J.LevyD. (1994). Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation89, 724–730. 10.1161/01.cir.89.2.724
98
VikmanS.LindgrenK.MäkikallioT. H.Yli-MäyryS.AiraksinenK. E. J.HuikuriH. V. (2005). Heart rate turbulence after atrial premature beats before spontaneous onset of atrial fibrillation. J. Am. Coll. Cardiol.45, 278–284. 10.1016/j.jacc.2004.10.033
99
VintherK. H.TveskovC.MöllerS.AuscherS.OsmanagicA.EgstrupK. (2017). Excessive premature atrial complexes and the risk of recurrent stroke or death in an ischemic stroke population. J. Stroke Cerebrovasc. Dis.26, 1163–1170. 10.1016/j.jstrokecerebrovasdis.2016.10.038
100
WaldoA. L. (2002). Mechanisms of atrial flutter and atrial fibrillation: Distinct entities or two sides of a coin?Cardiovasc. Res.54, 217–229. 10.1016/s0008-6363(01)00549-1
101
WangX.LiZ.MaoJ.HeB. (2017). Electrophysiological features and catheter ablation of symptomatic frequent premature atrial contractions. Europace19, 1535–1541. 10.1093/europace/euw152
102
XuY.ZhaoL.ZhangL.HanY.WangP.YuS. (2020). Left atrial enlargement and the risk of stroke: A meta-analysis of prospective cohort studies. Front. Neurol.11, 26. 10.3389/fneur.2020.00026
103
YamaneT.DateT.KanzakiY.InadaK.MatsuoS.ShibayamaK.et al (2006). Behavior of atrial ectopic beats before and after pulmonary vein isolation in patients with atrial fibrillation: A reduction in the number and arrhythmogenicity of ectopic firings. Heart rhythm.3, 1421–1427. 10.1016/j.hrthm.2006.08.023
104
YounisA.NofE.IsraelA.GoldenbergI.SabbagA.GliksonM.et al (2018). Relation of atrial premature complexes during exercise stress testing to the risk for the development of atrial fibrillation in patients undergoing cardiac rehabilitation. Am. J. Cardiol.122, 395–399. 10.1016/j.amjcard.2018.04.023
105
YueL.XieJ.NattelS. (2011). Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc. Res.89, 744–753. 10.1093/cvr/cvq329
106
Zoni BerissoM.FerroniA.De CaroE.CarratinoL.MelaG. S.VecchioC. (1986). Clinical significance of supraventricular tachyarrhythmias after acute myocardial infarction. Eur. Heart J.7, 743–748. 10.1093/oxfordjournals.eurheartj.a062135
Summary
Keywords
premature atrial contraction, nonsustained atrial arrhythmia, atrial cardiomyopathy, atrial fibrillation, ischemic stroke
Citation
Guichard J-B, Guasch E, Roche F, Da Costa A and Mont L (2022) Premature atrial contractions: A predictor of atrial fibrillation and a relevant marker of atrial cardiomyopathy. Front. Physiol. 13:971691. doi: 10.3389/fphys.2022.971691
Received
17 June 2022
Accepted
14 October 2022
Published
24 October 2022
Volume
13 - 2022
Edited by
Alina Scridon, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureş, Romania
Reviewed by
Tamas Szili-Torok, Erasmus Medical Center, Netherlands
Silvia Lupu, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureş, Romania
Updates
Copyright
© 2022 Guichard, Guasch, Roche, Da Costa and Mont.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jean-Baptiste Guichard, jbguichard@recerca.clinic.cat
This article was submitted to Cardiac Electrophysiology, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.